NOTE

🌱 created from: palliative_intent-of-hnscc

extreme

EXTREME trial: Cetuximab plus platinum-based chemotherapy significantly prolonged the median overall survival from 7.4 months to 10.1 months, improved median progression-free survival time from 3.3 to 5.6 months, and increased the response rate from 20% to 36% in patients with untreated recurrent or metastatic squamous-cell carcinoma of the head and neck.

1.Vermorken JB. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. The New England Journal of Medicine. Published September 11, 2008. Accessed September 28, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa0802656